Gold bars to be exempt from tariffs, White House clarifies
SAN DIEGO—Nancy Denyes, General Counsel at aTyr Pharma Inc. (NASDAQ:ATYR), recently reported a sale of company shares. According to a Form 4 filing with the Securities and Exchange Commission, Denyes sold 899 shares of common stock on February 4, 2025, at a price of $3.78 per share, totaling approximately $3,398. The transaction comes as aTyr’s stock shows significant momentum, with shares up over 108% in the past six months, according to InvestingPro data.
The transaction was part of a move to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). On February 3, 2025, Denyes acquired 2,687 shares of common stock through the vesting of RSUs, which convert on a one-for-one basis into common stock. This acquisition was made without any cost to Denyes. InvestingPro analysis indicates the company maintains strong liquidity with a current ratio of 5.41, though it’s currently trading above its Fair Value.
Following these transactions, Denyes holds a total of 26,555 shares in aTyr Pharma, a clinical-stage biotherapeutics company with a market capitalization of approximately $318 million. InvestingPro subscribers can access 13 additional key insights and a comprehensive Pro Research Report about aTyr’s financial health and market position.
In other recent news, aTyr Pharma has been making significant moves. Piper Sandler, a major investment bank, mentioned aTyr Pharma among six companies with expected de-risked Phase 3 readouts or interim analyses in 2025. The bank’s report is based on a thorough review of third-quarter 2024 earnings and year-end 2024 data.
Additionally, aTyr Pharma expanded its stock sale agreement with Jefferies LLC, allowing for potential additional sales of common stock shares. This amendment to the original agreement, which was fully utilized by aTyr Pharma, provides a framework for future sales at the company’s discretion.
The company also welcomed Eric Benevich, Chief Commercial Officer at Neurocrine (NASDAQ:NBIX) Biosciences, Inc., to its Board of Directors. Benevich’s three decades of pharmaceutical commercial experience are expected to be a valuable asset to aTyr as it moves toward the commercialization phase.
In a recent analysis, Lucid (NASDAQ:LCID) Capital Markets initiated coverage on aTyr Pharma with a Buy rating, focusing on the potential of Efzofitimod, aTyr Pharma’s lead candidate currently in a Global Phase 3 EFZO-FIT trial for Pulmonary Sarcoidosis. Lucid noted that the company is approaching significant milestones that could act as catalysts for the company’s stock. These developments underscore the dynamic nature of aTyr Pharma’s recent activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.